Advertisement
Research Article| Volume 1, ISSUE 3, P183-190, February 1979

Download started.

Ok

Plasma concentrations of unconjugated and conjugated estrogens and gonadotrophins following application of various estrogen preparations after oophorectomy and in the menopause

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      In 55 patients after oophorectomy and 20 women ater natural menopause an oral estrogen replacement therapy was performed with estrone-sulfate, estradiol 17-valerate, estriol-succinate, a combination of micronized estradiol and estriol (Estrifam®, Trisequens®), and natural conjugated estrogens. In 4 patients a 3 mg estradiol per 5 g ointment substance was applied on the abdominal skin.
      The interindividual variations of estrogen increments during therapy were considerably high. Oral intake of 2 mg estriol-succinate daily was followed by a 500% increase of total (conjugated + unconjugated) estriol. Concentrations of unconjugated estrogens were not altered by this dosage. Following oral application of the other above mentioned preparations, prominent rises - especially of unconjugated estrogens in plasma - were noted. The concentration peaks ocurred within 3–6 h after application. Unconjugated estradiol-17β in plasma was comparable with values of the follicular phase of a normal menstrual cycle, unconjugated estrone, however, was nonphysiologically high. Consequently, the E1/E2 ratio was greater than one whereas it is normally below one. 12 h after oral estrogen application, plasma estrogens dropped to almost initial values, so that a second medication seems to be necessary in order to guarantee an adequate supplementation over the course of the day.
      The hormone values determined in this study did not show significant differences between patients after a natural menopause and after oophorectomy. There was a positive correlation between rising estrogen levels and suppressed gonadotrophins during replacement therapy. The occurrence of climacteric symptoms did not exclusively depend on low estrogen and high gonadotrophin levels.
      Good tolerance of estrogen therapy with significantly elevated estrogen concentrations in plasma can be obtained transcutaneously in the form of estrogen ointments. Such therapy might simulate the physiological estrogen pattern even better than oral application does because of delayed and diluted steroid flow to the liver.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kaiser R.
        Die Östrogenausscheidung im Zyklus und nach Injektion von Östradiolestern.
        Geburtshilfe Fraunenheilkd. 1961; 21: 868-873
        • Leyendecker G.
        • Geppert G.
        • Nocke W.
        • Ufer J.
        Untersuchungen zur Pharmakokinetik von Östradiol-17β, Östradiol-Benzoat, Östradiol-Valerianat und Östradiol-Undezylat bei der Frau: Der Verlauf der Konzentrationen von Östradiol-17β, Östron, LH and FSH im Serum.
        Geburtshilfe Frauenheilkd. 1975; 35: 370-374
        • Greenblatt R.B.
        • Bruneteau D.H.
        • Merchandani J.
        Menopausal migraine.
        in: Greenblatt R.B. Mahesh V.B. McDonough P.G. The menopausal syndrome. Medcom Press, New York1974: 102-110
        • Luisi M.
        • Kicovic P.M.
        • Alicicco E.
        • Franchi F.
        Effects of estradiol decanoate in ovariectomized women.
        J. Endocrinol. Invest. 1978; 2: 101
        • Lebech P.E.
        Hormone therapy of the menopause.
        in: Greenblatt R.B. Mahesh V.B. McDonough P.G. The menopausal syndrome. Medcom Press, New York1974: 199-204
        • Sele V.
        The individual treatment of climacteric complaints.
        in: Branolte J. Brouwer W. van Keep P. Schellen T. Problemen van het climacterium in de medische praktijk. European Press, 1977: 93-99
        • Widholm O.
        • Vartiainen E.
        The absorption of conjugated oestrogen and sodium oestrone sulphate from the vagina.
        Ann. Chir. Gynaecol. Fenn. 1974; 63: 186-190
        • Schiff I.
        • Tulchinsky D.
        • Ryan K.J.
        Vaginal absorption of estrone and 17β-estradiol.
        The American Fertility Society. 1977; Vol. 28
        • Rigg L.A.
        • Milanes B.
        • Villanueva B.
        • Yen S.S.C.
        Efficacy of intravaginal and intranasal administration of micronized estradiol-17β.
        J. Clin. Endocrinol. Metab. 1977; 45: 1261
        • Strecker J.R.
        • Lauritzen Ch.
        Belastungstest zur Beurteilung der Plazentafunktion mit radioimmunologischer Bestimmung der Plasma-Oestrogene.
        Z. Geburtshilfe Perinatol. 1974; 178: 254
        • Yen S.S.C.
        • Martin P.L.
        • Burnier A.M.
        • Czekala N.M.
        • Greaney Jr., M.O.
        • Callantine M.R.
        Circulating estradiol, estrone and gonadotropin levels following the administration of orally active 17β-estradiol in postmenopausal women.
        J. Clin. Endocrinol. Metab. 1975; 40: 518
        • Longcope Ch.
        • Tait J.F.
        Validity of metabolic clearance and interconversion rates of estrone and 17β-estradiol in normal adults.
        J. Clin. Endocrinol. 1971; 32: 481
        • Siiteri P.K.
        • Schwarz B.F.
        • MacDonald P.C.
        Estrogen receptors and the estrone hypothesis in relation to endometrial and breast cancer.
        Gynecol. Oncol. 1974; 2: 228